|
gptkbp:instance_of
|
gptkb:healthcare_organization
|
|
gptkbp:associated_with
|
gptkb:ALK_gene
|
|
gptkbp:clinical_trial
|
NC T00000001
NC T00000002
NC T00000003
|
|
gptkbp:first_described_by
|
gptkb:1980s
|
|
gptkbp:genetic_diversity
|
gptkb:ALK_fusion_gene
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anaplastic large cell lymphoma, ALK-positive
|
|
gptkbp:is_characterized_by
|
chromosomal rearrangement
|
|
gptkbp:is_often_used_in
|
young adults
|
|
gptkbp:related_to
|
gptkb:healthcare_organization
gptkb:non-Hodgkin_lymphoma
|
|
gptkbp:research
|
ongoing
genetic studies
clinical studies
epidemiological studies
biomarker studies
molecular studies
therapeutic studies
pathological studies
survival studies
treatment outcome studies
|
|
gptkbp:risk_factor
|
genetic predisposition
viral infections
immune suppression
|
|
gptkbp:social_responsibility
|
gptkb:healthcare_organization
gptkb:anaplastic_lymphoma
rare
variable
more common in males
biopsy
immunohistochemistry
PET scan
incidence rate increasing
|
|
gptkbp:symptoms
|
weight loss
fever
lymphadenopathy
|
|
gptkbp:treatment
|
gptkb:hospital
gptkb:brentuximab_vedotin
gptkb:vaccine
gptkb:lorlatinib
gptkb:alectinib
gptkb:ceritinib
gptkb:crizotinib
palliative care
supportive care
radiation therapy
chemotherapy
targeted therapy
clinical observation
stem cell transplant
|
|
gptkbp:type_of
|
gptkb:secondary_ALCL
gptkb:systemic_ALCL
primary cutaneous ALCL
|
|
gptkbp:bfsParent
|
gptkb:ALK
|
|
gptkbp:bfsLayer
|
5
|